Inovio Pharmaceuticals Inc (INO)
4.07
+0.01
(+0.25%)
USD |
NASDAQ |
Nov 22, 16:00
4.08
+0.01
(+0.25%)
After-Hours: 20:00
Inovio Pharmaceuticals Research and Development Expense (Quarterly): 18.73M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 18.73M |
| June 30, 2024 | 23.09M |
| March 31, 2024 | 20.91M |
| December 31, 2023 | 17.25M |
| September 30, 2023 | 15.50M |
| June 30, 2023 | 23.74M |
| March 31, 2023 | 30.18M |
| December 31, 2022 | 42.12M |
| September 30, 2022 | 33.09M |
| June 30, 2022 | 56.46M |
| March 31, 2022 | 55.98M |
| December 31, 2021 | 92.30M |
| September 30, 2021 | 47.09M |
| June 30, 2021 | 70.81M |
| March 31, 2021 | 39.04M |
| December 31, 2020 | 26.30M |
| September 30, 2020 | 26.46M |
| June 30, 2020 | 22.38M |
| March 31, 2020 | 19.11M |
| December 31, 2019 | 22.00M |
| September 30, 2019 | 19.14M |
| June 30, 2019 | 22.49M |
| March 31, 2019 | 24.39M |
| December 31, 2018 | 26.37M |
| September 30, 2018 | 21.85M |
| Date | Value |
|---|---|
| June 30, 2018 | 22.46M |
| March 31, 2018 | 24.58M |
| December 31, 2017 | 24.64M |
| September 30, 2017 | 25.51M |
| June 30, 2017 | 23.88M |
| March 31, 2017 | 24.54M |
| December 31, 2016 | 23.91M |
| September 30, 2016 | 26.98M |
| June 30, 2016 | 19.63M |
| March 31, 2016 | 18.19M |
| December 31, 2015 | 15.60M |
| September 30, 2015 | 16.08M |
| June 30, 2015 | 16.69M |
| March 31, 2015 | 9.426M |
| December 31, 2014 | 9.244M |
| September 30, 2014 | 7.018M |
| June 30, 2014 | 9.607M |
| March 31, 2014 | 8.226M |
| December 31, 2013 | 6.404M |
| September 30, 2013 | 5.438M |
| June 30, 2013 | 4.411M |
| March 31, 2013 | 5.115M |
| December 31, 2012 | 4.443M |
| September 30, 2012 | 4.972M |
| June 30, 2012 | 4.527M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
15.50M
Minimum
Sep 2023
92.30M
Maximum
Dec 2021
35.13M
Average
26.38M
Median
Research and Development Expense (Quarterly) Benchmarks
| Novavax Inc | 87.16M |
| Baxter International Inc | 129.00M |
| AIM ImmunoTech Inc | 1.437M |
| Protalix BioTherapeutics Inc | 2.998M |
| Armata Pharmaceuticals Inc | 9.485M |